Much more research is needed to mechanistically better understand how TRPML1 or TPC2 inhibitors may impact melanoma development and progression in vivo and, most importantly, what consequences TRPML1/TPC2 inhibition, in particular long-term inhibition, would have. This evidence concerns the gene TPCN2 and melanoma.